Literature DB >> 8808438

Varioliform gastritis and duodenitis associated with protein-losing gastroenteropathy, treated with omeprazole.

I Murata1, I Yoshikawa, T Kuroda, A Tabaru, T Miura, M Otsuki.   

Abstract

A 44-year-old female with varioliform gastritis and duodenitis had gastrointestinal protein loss revealed by 111indium chloride scintigraphy. Treatment with omeprazole, a proton pump inhibitor, for 2 months, followed by famotidine, resulted in clinical improvement with resolution of the gastroduodenal lesions and protein loss. Colonization of the stomach with Helicobacter pylori was found before and after the treatment. The results in this patient suggest that omeprazole can be of value for the treatment of varioliform gastritis associated with protein-losing gastroenteropathy. The role of Helicobacter pylori in the pathogenesis of this disease is unclear.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8808438     DOI: 10.1007/bf01211196

Source DB:  PubMed          Journal:  J Gastroenterol        ISSN: 0944-1174            Impact factor:   7.527


  12 in total

1.  Chronic lymphocytic gastritis and protein losing gastropathy.

Authors:  J R Crampton; J O Hunter; G Neale; D G Wight
Journal:  Gut       Date:  1989-11       Impact factor: 23.059

2.  Indium-111 transferrin imaging for the diagnosis of protein-losing enteropathy.

Authors:  T Aburano; K Yokoyama; S Kinuya; T Takayama; N Tonami; K Hisada; T Ueno; R Takeda
Journal:  Clin Nucl Med       Date:  1989-09       Impact factor: 7.794

3.  Lymphocytic gastritis: a newly described entity: a retrospective endoscopic and histological study.

Authors:  J Haot; L Hamichi; L Wallez; P Mainguet
Journal:  Gut       Date:  1988-09       Impact factor: 23.059

4.  [Helicobacter pylori-associated hypertrophic gastritis. Imitation of Ménétrier disease].

Authors:  R Herz; E Lombardi; F Wipping; M Stolte
Journal:  Fortschr Med       Date:  1992-02-10

5.  Giant hypertrophic gastropathy (Ménétrier's disease): pharmacologic effects on protein leakage and mucosal ultrastructure.

Authors:  D G Kelly; L J Miller; J R Malagelada; K A Huizenga; H Markowitz
Journal:  Gastroenterology       Date:  1982-09       Impact factor: 22.682

6.  Intestinal clearance of alpha 1-antitrypsin. A sensitive method for the detection of protein-losing enteropathy.

Authors:  C Florent; C L'Hirondel; C Desmazures; C Aymes; J J Bernier
Journal:  Gastroenterology       Date:  1981-10       Impact factor: 22.682

7.  Diagnosis of protein-losing enteropathy by gastrointestinal clearance of alpha1-antitrypsin.

Authors:  J J Bernier; C Florent; C Desmazures; C Aymes; C L'Hirondel
Journal:  Lancet       Date:  1978-10-07       Impact factor: 79.321

8.  Transient protein losing enteropathy associated with acute gastritis and campylobacter pylori.

Authors:  I D Hill; C Sinclair-Smith; A J Lastovica; M D Bowie; M Emms
Journal:  Arch Dis Child       Date:  1987-12       Impact factor: 3.791

9.  Octreotide reduces enteral protein losses in Ménétrier's disease.

Authors:  P Yeaton; H F Frierson
Journal:  Am J Gastroenterol       Date:  1993-01       Impact factor: 10.864

10.  Gastritis varioliformis. Chronic erosive gastritis with protein-losing gastropathy.

Authors:  A C Clarke; S P Lee; G I Nicholson
Journal:  Am J Gastroenterol       Date:  1977-12       Impact factor: 10.864

View more
  3 in total

1.  Fecal clearance of alpha1-antitrypsin with lansoprazole can detect protein-losing gastropathy.

Authors:  H Takeda; S Nishise; M Furukawa; R Nagashima; H Shinzawa; T Takahashi
Journal:  Dig Dis Sci       Date:  1999-11       Impact factor: 3.199

2.  Protein-Losing Enteropathy and Gastropathy.

Authors:  Brian R. Landzberg; Mark B. Pochapin
Journal:  Curr Treat Options Gastroenterol       Date:  2001-02

3.  Factors affecting occurrence of gastric varioliform lesions: A case-control study.

Authors:  Tian-Hui Zou; Ru-Hua Zheng; Qin-Yan Gao; Xuan Kong; Xiao-Yu Chen; Zhi-Zheng Ge; Ying-Xuan Chen; Xiao-Ping Zou; Jing-Yuan Fang
Journal:  World J Gastroenterol       Date:  2016-06-14       Impact factor: 5.742

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.